128 related articles for article (PubMed ID: 26168370)
1. Rituximab Therapy in Neuromyelitis Optica: Moving Toward a Personalized Medicine Approach.
Tobin WO; Pittock SJ
JAMA Neurol; 2015 Sep; 72(9):974-7. PubMed ID: 26168370
[No Abstract] [Full Text] [Related]
2. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
4. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
5. Capillary leak syndrome in neuromyelitis optica treated with rituximab.
Fuentes Fernandez I; Hernandez-Clares R; Carreón Guarnizo E; Meca Lallana JE
Mult Scler Relat Disord; 2017 Aug; 16():22-23. PubMed ID: 28755680
[TBL] [Abstract][Full Text] [Related]
6. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
[TBL] [Abstract][Full Text] [Related]
7. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
9. Hiccups as Herald: Neuromyelitis Optica Spectrum Disorder.
Puri A; Chesser M; Chan K; Kharidi V
Am J Med; 2017 Sep; 130(9):1055-1058. PubMed ID: 28599993
[No Abstract] [Full Text] [Related]
10. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
11. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
[TBL] [Abstract][Full Text] [Related]
12. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
Woo MS; Steins D; Häußler V; Kohsar M; Haag F; Elias-Hamp B; Heesen C; Lütgehetmann M; Schulze Zur Wiesch J; Friese MA
J Neurol; 2021 Jan; 268(1):5-7. PubMed ID: 32654064
[No Abstract] [Full Text] [Related]
13. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
14. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).
Vaknin-Dembinsky A; Charbit H; Brill L; Abramsky O; Gur-Wahnon D; Ben-Dov IZ; Lavon I
J Neuroinflammation; 2016 Jul; 13(1):179. PubMed ID: 27393339
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran.
Sahraian MA; Azimi A; Navardi S; Rezaeimanesh N; Naser Moghadasi A
Mult Scler Relat Disord; 2020 Sep; 44():102245. PubMed ID: 32512287
[No Abstract] [Full Text] [Related]
17. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
Capobianco M; Malucchi S; di Sapio A; Gilli F; Sala A; Bottero R; Marnetto F; Doriguzzi Bozzo C; Bertolotto A
Neurol Sci; 2007 Aug; 28(4):209-11. PubMed ID: 17690854
[TBL] [Abstract][Full Text] [Related]
18. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
19. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
Maillart E; Lippi A; Lubetzki C; Louapre C; Papeix C
Mult Scler Relat Disord; 2018 Feb; 20():220-222. PubMed ID: 29433095
[TBL] [Abstract][Full Text] [Related]
20. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
